TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12072104

Group type: EXPERIMENTAL
Intervention: HBV vaccination with levamisole (80 mg after each hemodialysis session for 4 months)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Second HBV vaccination program with levamisole
Number of subjects: 96

Group type: COMPARATOR
Intervention: Second HBV vaccination program without levamisole
Number of subjects: 96

Group type: COMPARATOR
Intervention: HBV vaccination without levamisole
Number of subjects: 96
Study: 10084038

Group type: EXPERIMENTAL
Intervention: Periarticular injection of 1.5 ml (40 mg/ml) methylprednisolone acetate and 1.5 ml (20 mg/ml) lignocaine (MP group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic sodium chloride and 1.5 ml (20 mg/ml) lignocaine (non‐MP group)
Number of subjects: 20
Study: 8571928

Group type: EXPERIMENTAL
Intervention: Press needle technique (PN)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: In-situ technique (IS)
Number of subjects: 31
Study: 2187525

Group type: COMPARATOR
Intervention: Intravenous treosulfan
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intravenous treosulfan plus cisplatinum
Number of subjects: 135
Study: 6142462

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 to 1 mg 3-times daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 30
Study: 30370983

Group type: EXPERIMENTAL
Intervention: Active deep rTMS (1 Hz at 120% of individual motor threshold)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 16
Study: 29083258

Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg once daily for 24 weeks
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 26791921

Group type: EXPERIMENTAL
Intervention: High-dose caffeine (loading 20 mg/kg and maintenance of 15 mg/(kg·d) after 24 h)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Low-dose caffeine (loading 20 mg/kg and maintenance of 5 mg/(kg·d) after 24 h)
Number of subjects: 164
Study: 24902983

Group type: EXPERIMENTAL
Intervention: USL255 (200 mg/day)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 21960311

Group type: EXPERIMENTAL
Intervention: CAPIRI/CAPOX plus cetuximab
Number of subjects: 146
Study: 19649708

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 20238281

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (group 1, verum open, N = 4)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (group 2, verum blind, N = 3)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (group 3, placebo blind, N = 4)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All groups (including both verum and placebo)
Number of subjects: 11
Study: 16218261

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Ondansetron/Dolasetron
Number of subjects: 171
Study: 12398958

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Uncoated metal stent (UMS)
Number of subjects: 238
Study: 9973769

Group type: EXPERIMENTAL
Intervention: 2.0 g vitamin C
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (for vitamin C trial)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 105 g carbohydrate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (for carbohydrate trial)
Number of subjects: 17
Study: 7923512

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (100 micrograms)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (100 micrograms)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cross-over patients (41 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 100

Group type: COMPARATOR
Intervention: Epidural fentanyl
Number of subjects: 100
Study: 3262637

Group type: EXPERIMENTAL
Intervention: Active device (electrical stimulation applied to the tongue and hard palate)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Active device
Number of subjects: 29
Study: 27359164

Group type: EXPERIMENTAL
Intervention: Brief Parent Training (BPT)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Parent Management Training, Oregon Model (PMTO)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Individual Social Skills Training (ISST)
Number of subjects: 551
Study: 27058647

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 34
Study: 25362110

Group type: EXPERIMENTAL
Intervention: 160 mg of aspirin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22494121

Group type: EXPERIMENTAL
Intervention: Rectal indomethacin
Number of subjects: 602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study: 20719809

Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone (200 mg, 3 times a day)
Number of subjects: 468

Group type: COMPARATOR
Intervention: No luteal phase support
Number of subjects: 468
Study: 18519268

Group type: EXPERIMENTAL
Intervention: Continuous-combined hormone replacement therapy (ccHRT) with estradiol valerate/medroxyprogesterone acetate (E(2)V/MPA) at dosages of 1 mg + 2.5 mg (n = 69), 1 mg + 5 mg (n = 70), or 2 mg + 5 mg (n = 140) for 8.5 years.
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Continuous-combined hormone replacement therapy (ccHRT) with estradiol valerate/medroxyprogesterone acetate (E(2)V/MPA)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Post-discontinuation of ccHRT
Number of subjects: 279
Study: 16170117

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 451

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 451
Study: 12855348

Group type: EXPERIMENTAL
Intervention: Surgical intervention involving sectioning of the tendon to the internal obturator muscle near its insertion at the trochanter
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (no surgical intervention)
Number of subjects: 6
Study: 10491352

Group type: COMPARATOR
Intervention: BRS(Phe)
Number of subjects: 49

Group type: COMPARATOR
Intervention: BRS(alphaLF)
Number of subjects: 49

Group type: COMPARATOR
Intervention: BRS(alphaHF)
Number of subjects: 49

Group type: COMPARATOR
Intervention: BRS(Seq)
Number of subjects: 49

Group type: COMPARATOR
Intervention: BRS(Cbr)
Number of subjects: 49
Study: 8559529

Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 gel
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 1724669

Group type: EXPERIMENTAL
Intervention: Iloprost infusion (0.5-0.2 ng/kg/min for 6 hours per day for 2 weeks)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo infusion for 2 weeks
Number of subjects: 102
Study: 6343462

Group type: EXPERIMENTAL
Intervention: Fluocortin butyl (FCB) 2 mg
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Fluocortin butyl (FCB) 4 mg
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Fluocortin butyl (FCB) 8 mg
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 30804399

Group type: EXPERIMENTAL
Intervention: Chiropractic care intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive movement control
Number of subjects: 12
Study: 30341154

Group type: EXPERIMENTAL
Intervention: FACE pACP (pediatric advance care planning survey, Respecting Choices interview, 5 Wishes directive)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (developmental history, safety tips, nutrition and exercise tips)
Number of subjects: 105
Study: 26990694

Group type: EXPERIMENTAL
Intervention: Tacrolimus dosage determined by CYP3A5 genotype
Number of subjects: 236

Group type: COMPARATOR
Intervention: Fixed dosage of tacrolimus
Number of subjects: 236
Study: 24572452

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1‐α hydroxyvitamin D3)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 22013959

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel injection (2 ml, 3.5% micronised hyaluronic acid) using the fan technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel injection (2 ml, 3.5% micronised hyaluronic acid) using the multiple puncture technique
Number of subjects: 60
Study: 20846688

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin with recommended daily allowance vitamins
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin with megadose vitamins
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin/interferon α‐2b with recommended daily allowance vitamins
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin/interferon α‐2b with megadose vitamins
Number of subjects: 670

Group type: COMPARATOR
Intervention: Bacillus Calmette‐Guérin alone
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin plus interferon α‐2b
Number of subjects: 670
Study: 17604562

Group type: EXPERIMENTAL
Intervention: Quyu Xiaoban capsules (QYXB) plus aspirin (300 mg loading dose, 100 mg maintenance dose)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Aspirin (300 mg loading dose, 100 mg maintenance dose) plus baseline therapy
Number of subjects: 90
Study: 16220098

Group type: EXPERIMENTAL
Intervention: Neuraminidase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients (Control)
Number of subjects: 0
Study: 11215574

Group type: EXPERIMENTAL
Intervention: Clozapine (mean dose 28.78 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 53
Study: 9623930

Group type: EXPERIMENTAL
Intervention: Treatment and sterilization guidelines introduced; seminars held at health centres; assessed 4 months post-intervention.
Number of subjects: 66
Study: 8075732

Group type: EXPERIMENTAL
Intervention: Computer-generated telephone reminder or recall message
Number of subjects: 8002

Group type: COMPARATOR
Intervention: No message (control group)
Number of subjects: 8002

Group type: EXPERIMENTAL
Intervention: Computer-generated telephone message received
Number of subjects: 8002
Study: 2811066

Group type: EXPERIMENTAL
Intervention: Calcium acetate (50 mEq Ca++)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Calcium carbonate (50 mEq Ca++)
Number of subjects: 6
Study: 803895

Group type: EXPERIMENTAL
Intervention: Carbohydrate mixture of fructose, glucose and xylitol (2:1:1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fructose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Xylitol
Number of subjects: 0
Study: 30816851

Group type: EXPERIMENTAL
Intervention: Simultaneous (weight and diet tracking with weekly lessons, action plans, and feedback)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Sequential (weight tracking for 4 weeks, then added diet tracking with the same behavioral components)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: App-Only (only diet tracking)
Number of subjects: 105
Study: 28432876

Group type: EXPERIMENTAL
Intervention: Pistachio-supplemented diet (PD, 50% carbohydrates, 33% fat, including 57 g/d of pistachios daily)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pistachio-supplemented diet (PD)
Number of subjects: 39
Study: 25474490

Group type: EXPERIMENTAL
Intervention: Polysomnography for diagnosis of OSAS
Number of subjects: 453
Study: 23673889

Group type: EXPERIMENTAL
Intervention: SISTA South Africa intervention
Number of subjects: 342

Group type: COMPARATOR
Intervention: General health comparison
Number of subjects: 342
Study: 21843366

Group type: EXPERIMENTAL
Intervention: REFRESH Program (intervention group)
Number of subjects: 900

Group type: COMPARATOR
Intervention: No intervention materials (control group)
Number of subjects: 900
Study: 19536165

Group type: EXPERIMENTAL
Intervention: Daily replacement of one meal with a low-calorie diet formula
Number of subjects: 62

Group type: COMPARATOR
Intervention: Dieting alone for another 6 months
Number of subjects: 62
Study: 17352632

Group type: EXPERIMENTAL
Intervention: 904-nm low-level laser irradiation (10 mW/cm² power density, 4 mW output power, 0.4 cm² spot size, 0.48 J dose per session, 120-sec treatment time)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo-laser therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparison of Group I and Group II
Number of subjects: 52
Study: 15083437

Group type: EXPERIMENTAL
Intervention: Partial weight‐bearing supported treadmill gait training augmented by functional electric stimulation (FES) for 25 minutes a day, 5 days a week for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard physiotherapy (PT) for 4 weeks
Number of subjects: 14
Study: 11444788

Group type: COMPARATOR
Intervention: Continuous dinoprostone
Number of subjects: 118

Group type: COMPARATOR
Intervention: Misoprostol 35-microg suppositories
Number of subjects: 118

Group type: COMPARATOR
Intervention: Misoprostol 50-microg suppositories
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Combined misoprostol groups
Number of subjects: 118
Study: 9097265

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ribavirin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 8458802

Group type: EXPERIMENTAL
Intervention: Thermoneutral cycling (32-35 degrees C)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Passive warm water exposure (39-41 degrees C)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cold cycling (18-23 degrees C)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Quiet rest (22 +/- 1 degrees C)
Number of subjects: 11
Study: 2870351

Group type: EXPERIMENTAL
Intervention: Multifactorial prevention intervention
Number of subjects: 60881
Study: 30714092

Group type: EXPERIMENTAL
Intervention: High hyperdiploid relapses
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Low hyperdiploid relapses
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Evident or masked hypodiploid relapses
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Hypodiploidy
Number of subjects: 413

Group type: COMPARATOR
Intervention: Current relapse risk stratification
Number of subjects: 413
Study: 30041588

Group type: EXPERIMENTAL
Intervention: MOVE SMI
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: WebMOVE
Number of subjects: 276

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 276
Study: 26879036

Group type: EXPERIMENTAL
Intervention: ImPAT (psychosocial pain management intervention)
Number of subjects: 129

Group type: COMPARATOR
Intervention: SPC (supportive psychoeducational control)
Number of subjects: 129
Study: 24682502

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22588152

Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy in T2a patients with KRAS wild-type tumors
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy in T2a patients with KRAS mutant tumors
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy in T2b to T3 patients with KRAS wild-type tumors
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy in T2b to T3 patients with KRAS mutant tumors
Number of subjects: 538
Study: 21265908

Group type: EXPERIMENTAL
Intervention: Combined student-parent intervention
Number of subjects: 3490

Group type: EXPERIMENTAL
Intervention: Parent intervention
Number of subjects: 3490

Group type: EXPERIMENTAL
Intervention: Student intervention
Number of subjects: 3490

Group type: COMPARATOR
Intervention: Regular curriculum
Number of subjects: 3490
Study: 17873571

Group type: EXPERIMENTAL
Intervention: Administration of antipyretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changing of indwelling catheters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alteration in antimicrobial therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appropriate measurement of body temperature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnostic evaluation
Number of subjects: 0
Study: 15955899

Group type: EXPERIMENTAL
Intervention: 75 mg temsirolimus
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 250 mg temsirolimus
Number of subjects: 109
Study: 12922087

Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine administered in one injection
Number of subjects: 235

Group type: COMPARATOR
Intervention: DTPa-IPV/Hib and HBV vaccines administered in two simultaneous injections
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Immunogenicity analysis for DTPa-HBV-IPV/Hib
Number of subjects: 235

Group type: COMPARATOR
Intervention: Immunogenicity analysis for DTPa-IPV/Hib and HBV
Number of subjects: 235
Study: 10385357

Group type: EXPERIMENTAL
Intervention: Fuji IX
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ChemFil Superior
Number of subjects: 23
Study: 8672710

Group type: EXPERIMENTAL
Intervention: Generalized estimating equations (GEE) approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seemingly unrelated regression paradigm
Number of subjects: 0
Study: 1499875

Group type: EXPERIMENTAL
Intervention: Gabexate mesylate (FOY) 12 mg/kg/day as continuous intravenous infusion for a minimum of 4 days and a maximum of 12 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 6580858

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 20 mg/kg/day for three consecutive days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral prednisone regime
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral prednisone
Number of subjects: 17
Study: 3534764

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (single drug therapy)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ampicillin-gentamicin-metronidazole (triple combination)
Number of subjects: 44
Study: 31603002

Group type: EXPERIMENTAL
Intervention: Intradialytic aerobic exercise with blood flow restriction
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional exercise
Number of subjects: 66

Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 66
Study: 29786702

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (H2O2) gel
Number of subjects: 35

Group type: COMPARATOR
Intervention: 37.5% hydrogen peroxide (H2O2) gel
Number of subjects: 35
Study: 28051341

Group type: EXPERIMENTAL
Intervention: High-compression pressure (HI) group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-compression pressure (LOW) group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham ultrasound group (SHAM)
Number of subjects: 45
Study: 26098729

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 23092714

Group type: EXPERIMENTAL
Intervention: rAd-Erns-E2 (2×10(6) TCID(50) administered intramuscularly two times with a 21-day interval)
Number of subjects: 9

Group type: COMPARATOR
Intervention: hAd-CMV control (3 pigs)
Number of subjects: 9

Group type: COMPARATOR
Intervention: DMEM control (3 pigs)
Number of subjects: 9
Study: 21534640

Group type: EXPERIMENTAL
Intervention: Pharmacist-physician collaborative practice
Number of subjects: 199

Group type: COMPARATOR
Intervention: Usual care (physician only)
Number of subjects: 199
Study: 18162322

Group type: EXPERIMENTAL
Intervention: Acute exercise bout (cycling)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: McArdle patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy sedentary controls
Number of subjects: 31
Study: 16340480

Group type: EXPERIMENTAL
Intervention: Cell-free virus (CFV)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cell-associated virus (CAV)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: CAV
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: CFV
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of CFV
Number of subjects: 122
Study: 12478111

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG)
Number of subjects: 2749

Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 2749

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG) maintenance
Number of subjects: 2749
Study: 10889283

Group type: EXPERIMENTAL
Intervention: vbCBT + paroxetine
Number of subjects: 33

Group type: COMPARATOR
Intervention: vbCBT + placebo
Number of subjects: 33
Study: 9112320

Group type: EXPERIMENTAL
Intervention: Nonoperative care (including medications, exercise, injection therapy, and manipulation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural history of disc resorption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflammation's effect on treatment effectiveness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Operative versus nonoperative care
Number of subjects: 0
Study: 1426660

Group type: EXPERIMENTAL
Intervention: Ribosomal vaccine (D53)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3872688

Group type: EXPERIMENTAL
Intervention: Fendosal with food (200 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fendosal with antacid (200 mg)
Number of subjects: 24
Study: 31772157

Group type: EXPERIMENTAL
Intervention: MRM retrieval + ketamine (RET + KET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketamine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retrieval alone
Number of subjects: 0
Study: 29943508

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with adrenaline 2 μg/mL
Number of subjects: 41

Group type: COMPARATOR
Intervention: Epidural analgesia without adrenaline (Control)
Number of subjects: 41
Study: 27130166

Group type: COMPARATOR
Intervention: DVD-based training (50 minutes)
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: App-based training (30 minutes)
Number of subjects: 1232
Study: 24592958

Group type: EXPERIMENTAL
Intervention: End-of-life care communication provided by physicians-in-training (internal medicine residents and medical subspecialty fellows)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: End-of-life care communication provided by physicians-in-training
Number of subjects: 0